Compile Data Set for Download or QSAR
Report error Found 168 Enz. Inhib. hit(s) with all data for entry = 6202
TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 50574215BDBM50574215(CHEMBL4878875 | US20240000767, Example 102 | US125...)
Affinity DataIC50: 0.0850nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 50574218BDBM50574218(CHEMBL4875484 | US20240000767, Example 135 | US125...)
Affinity DataIC50: 0.260nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 50574219BDBM50574219(CHEMBL4852159 | US20240000767, Example 140 | US125...)
Affinity DataIC50: 0.320nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 50574216BDBM50574216(CHEMBL4876214 | US20240000767, Example 108 | US125...)
Affinity DataIC50: 0.370nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 50574220BDBM50574220(CHEMBL4868807 | US20240000767, Example 143 | US125...)
Affinity DataIC50: 0.420nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643032BDBM643032(US20240000767, Example 111 | diamix-N-[(3,5-Difluo...)
Affinity DataIC50: 0.490nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 50574217BDBM50574217(CHEMBL4866383 | US20240000767, Example 126 | US125...)
Affinity DataIC50: 0.490nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643027BDBM643027(US20240000767, Example 106 | ent-N-[(3,5-Difluorop...)
Affinity DataIC50: 0.5nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643051BDBM643051(US20240000767, Example 130 | N-[(3,5-Difluoropyrid...)
Affinity DataIC50: 0.540nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643037BDBM643037(US20240000767, Example 116 | ent-2-{3-[(Cyclopropy...)
Affinity DataIC50: 0.610nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 790459BDBM790459(diamix-N-(5-Chloro-2-fluorobenzyl)-2-[(3R)-3'-fluo...)
Affinity DataIC50: 0.610nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643038BDBM643038(US20240000767, Example 117 | diamix-N-[1-(2,5-Difl...)
Affinity DataIC50: 0.650nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643060BDBM643060(US20240000767, Example 139 | US12540134, Example 1...)
Affinity DataIC50: 0.650nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643042BDBM643042(US20240000767, Example 121 | rac-N-[(3,5-Difluorop...)
Affinity DataIC50: 0.650nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643053BDBM643053(US20240000767, Example 132 | ent-2-[4-(1,1-Difluor...)
Affinity DataIC50: 0.710nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643055BDBM643055(US20240000767, Example 134 | diamix-2-[4-(1,1-Difl...)
Affinity DataIC50: 0.740nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643024BDBM643024(US20240000767, Example 103 | rac-N-[(3,5-Difluorop...)
Affinity DataIC50: 0.830nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643030BDBM643030(US20240000767, Example 109 | rac-2-[3-(Cyclobutylo...)
Affinity DataIC50: 0.850nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643054BDBM643054(US20240000767, Example 133 | rac-N-[(3,5-Difluorop...)
Affinity DataIC50: 0.950nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643066BDBM643066(US20240000767, Example 145 | US12540134, Example 1...)
Affinity DataIC50: 1nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643033BDBM643033(US20240000767, Example 112 | diamix-N-[(3,5-Difluo...)
Affinity DataIC50: 1.20nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643068BDBM643068(US20240000767, Example 148 | US12540134, Example 1...)
Affinity DataIC50: 1.30nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643035BDBM643035(US20240000767, Example 114 | 2-[(3R)-3-(Cyclopropy...)
Affinity DataIC50: 1.30nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 642986BDBM642986(US20240000767, Example 64 | 2-[4-(5-Azaspiro[2.5]o...)
Affinity DataIC50: 1.40nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 50574217BDBM50574217(CHEMBL4866383 | US20240000767, Example 126 | US125...)
Affinity DataIC50: 1.5nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643031BDBM643031(US20240000767, Example 110 | rac-2-{3-[(3,3-Difluo...)
Affinity DataIC50: 1.5nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643067BDBM643067(US20240000767, Example 146 | US12540134, Example 1...)
Affinity DataIC50: 1.72nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643065BDBM643065(US20240000767, Example 144 | US12540134, Example 1...)
Affinity DataIC50: 1.80nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643053BDBM643053(US20240000767, Example 132 | ent-2-[4-(1,1-Difluor...)
Affinity DataIC50: 1.90nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 642989BDBM642989(US20240000767, Example 67 | rac-2-[3-(Cyclopropylm...)
Affinity DataIC50: 2.20nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643044BDBM643044(US20240000767, Example 123 | ent-N-[(3,5-Difluorop...)
Affinity DataKi:  2.30nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 50574215BDBM50574215(CHEMBL4878875 | US20240000767, Example 102 | US125...)
Affinity DataIC50: 2.30nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 50574217BDBM50574217(CHEMBL4866383 | US20240000767, Example 126 | US125...)
Affinity DataIC50: 2.30nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 50574218BDBM50574218(CHEMBL4875484 | US20240000767, Example 135 | US125...)
Affinity DataIC50: 2.5nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643032BDBM643032(US20240000767, Example 111 | diamix-N-[(3,5-Difluo...)
Affinity DataIC50: 2.70nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 642986BDBM642986(US20240000767, Example 64 | 2-[4-(5-Azaspiro[2.5]o...)
Affinity DataKi:  2.80nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643021BDBM643021(US20240000767, Example 99 | ent-N-[(3,5-Difluoropy...)
Affinity DataIC50: 2.90nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643044BDBM643044(US20240000767, Example 123 | ent-N-[(3,5-Difluorop...)
Affinity DataIC50: 2.90nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 642929BDBM642929(US20240000767, Example 3 | 2-[3-(Cyclopropylmethyl...)
Affinity DataIC50: 2.90nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 50574215BDBM50574215(CHEMBL4878875 | US20240000767, Example 102 | US125...)
Affinity DataIC50: 4.30nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643025BDBM643025(US20240000767, Example 104 | ent-N-[(3,5-Difluorop...)
Affinity DataIC50: 4.30nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643053BDBM643053(US20240000767, Example 132 | ent-2-[4-(1,1-Difluor...)
Affinity DataIC50: 4.5nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643044BDBM643044(US20240000767, Example 123 | ent-N-[(3,5-Difluorop...)
Affinity DataIC50: 5.10nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 642924BDBM642924(US20240000767, Example 2 | N-[(3,5-Difluoropyridin...)
Affinity DataIC50: 5.20nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643037BDBM643037(US20240000767, Example 116 | ent-2-{3-[(Cyclopropy...)
Affinity DataIC50: 5.5nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 642986BDBM642986(US20240000767, Example 64 | 2-[4-(5-Azaspiro[2.5]o...)
Affinity DataIC50: 6.20nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643059BDBM643059(US20240000767, Example 138 | US12540134, Example 1...)
Affinity DataIC50: 6.5nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 642972BDBM642972(US20240000767, Example 51 | US20240000767, Example...)
Affinity DataIC50: 6.70nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 643063BDBM643063(US20240000767, Example 142 | US12540134, Example 1...)
Affinity DataIC50: 6.70nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

TargetAlpha-2C adrenergic receptor(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 642947BDBM642947(US20240000767, Example 21 | N-(5-Chloro-2-fluorobe...)
Affinity DataIC50: 7.20nMAssay Description:The efficacy of the compounds of Formula (I) can also be determined in cell-based killing assays using a variety of cell lines and mouse tumor models...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/15/2026
Entry Details US Patent

Displayed 1 to 50 (of 168 total ) | Next | Last >>
Jump to: